title: 100 mg acetylsalicylic acid acutely decreases red cell aggregation in women taking oral contraceptives.
abstract: Since oral contraceptives (OC) are known to impair blood fluidity and to increase the risk of venous and arterial thrombosis, while acetylsalicylic acid (ASA) decreases the thrombotic risk and modifies some rheologic parameters, we compared the hemorheologic effects of ASA on blood rheology between women treated by OC and women who never received this medication. 25 women under OC were compared to 25 matched women who had never used OC. Blood viscosity (MT90 viscometer) and RBC aggregation (Myrenne aggregometer and AFFIBIO erythroaggregometer) were measured before and 1 hr after women received per os 100 mg ASA, after an overnight fast. The only significant difference between women under OC and controls was an increased RBC aggregation ('M' index +28%, p < 0.04; Affibio aggregation time -21%, p < 0.03). On the whole sample of 50 women as well as in the subgroup of women under OC, ASA decreased RBC partial disaggregation threshold (-1.7%, p < 0.01). These results confirm that RBC aggregation is increased under OC and suggest that 100 mg ASA acutely induces a partial reversal of this RBC hyperaggregation.
authors.affiliation: Service de Gynécologie Obstétrique, Hôpital Arnaud de Villeneuve, France.
authors.forename: A
authors.initials: A
authors.lastname: El Bouhmadi
authors.forename: F
authors.initials: F
authors.lastname: Laffargue
authors.forename: N
authors.initials: N
authors.lastname: Raspal
authors.forename: J F
authors.initials: JF
authors.lastname: Brun
mesh_terms: D000328:Adult; D001241:Aspirin / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001809:Blood Viscosity / Q000187:drug effects*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects / Q000494:pharmacology*; D003278:Contraceptives, Oral, Hormonal / Q000009:adverse effects / Q000494:pharmacology*; D017373:Cyproterone Acetate / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D004903:Erythrocyte Aggregation / Q000187:drug effects*; D004907:Erythrocyte Deformability / Q000187:drug effects; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D018056:Hemorheology / Q000295:instrumentation; D006801:Humans; D009640:Norethindrone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D000077563:Norethindrone Acetate; D009644:Norgestrel / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D019851:Thrombophilia / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D005343:Fibrinolytic Agents; D009644:Norgestrel; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; D000077563:Norethindrone Acetate; D001241:Aspirin; D009640:Norethindrone